1 completed, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Trastuzumab IV: new trials by email Literature Review of Trastuzumab IV trials Research Report on Trastuzumab IV
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV - HER2-Positive Early Breast Cancer | Phase 2 | Completed | Hoffmann-La Roche | 160 | 2018-12-19 | 2024-01-02 |
| Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer Patients Trastuzumab IV, Trastuzumab SC, Pertuzumab - Cancer, Breast | Phase 2 | Unknown | Gruppo Oncologico Italiano di Ricerca Clinica | 65 | 2016-11-29 | 2020-10-14 |
Breast Neoplasms (1)
Gruppo Oncologico Italiano di Ricerca Clinica (1) · Hoffmann-La Roche (1)
Argentina (1) · Brazil (1) · Chile (1) · Cuba (1) · Finland (1) · Hong Kong (1) · Italy (1) · Jordan (1) · Lebanon (1) · Mexico (1) · Panama (1) · Portugal (1) · Qatar (1) · Saudi Arabia (1) · Serbia (1)
PMID 34147014, PMID 38016718, PMID 40461387
2018 (1)